Study details
Enrolling now
A Study on Bimekizumab in Breast Milk
UCB Biopharma SRL
NCT IDNCT06888193ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
20
Study length
about 1.5 years
Ages
18+
Sex
Female only
Locations
4 sites in CA, FL, NC +1
About this study
Researchers are testing how much bimekizumab, a medication, ends up in breast milk from mothers who are being treated with bimzelx®. The trial will last for 544 days and involve approximately 20 women.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Bimekizumab
PhasePhase 1
DrugBimekizumab
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
bimekizumab
Endpoints
Secondary: Treatment-emergent Adverse Events (TEAEs) of the mother from time of informed consent through SFU contact
Body systems
Dermatology